Literature DB >> 22455420

To be 17 again--anti-interleukin-17 treatment for psoriasis.

Ari Waisman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22455420     DOI： 10.1056/NEJMe1201071

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  13 in total

1.  IL-6 regulates neutrophil microabscess formation in IL-17A-driven psoriasiform lesions.

Authors:  Andrew L Croxford; Susanne Karbach; Florian C Kurschus; Simone Wörtge; Alexei Nikolaev; Nir Yogev; Sabrina Klebow; Rebecca Schüler; Sonja Reissig; Carolin Piotrowski; Elke Brylla; Ingo Bechmann; Jürgen Scheller; Stefan Rose-John; F Thomas Wunderlich; Thomas Münzel; Esther von Stebut; Ari Waisman
Journal:  J Invest Dermatol       Date:  2013-09-25       Impact factor: 8.551

2.  Expression of IL-17F is associated with non-pathogenic Th17 cells.

Authors:  Florian Wanke; Yilang Tang; Konrad Gronke; Sabrina Klebow; Sonja Moos; Judith Hauptmann; Arthi Shanmugavadivu; Tommy Regen; Ilgiz A Mufazalov; Lauren A Gabriel; Sonja Reißig; Andreas Diefenbach; Florian C Kurschus; Ari Waisman
Journal:  J Mol Med (Berl)       Date:  2018-06-29       Impact factor: 4.599

3.  Autoimmunity beyond Th17: GM-CSF producing T cells.

Authors:  Christina E Zielinski
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 4.  Adaptive immunity in atherogenesis: new insights and therapeutic approaches.

Authors:  Andrew H Lichtman; Christoph J Binder; Sotirios Tsimikas; Joseph L Witztum
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

5.  Protein kinase CK2 governs the molecular decision between encephalitogenic TH17 cell and Treg cell development.

Authors:  Alexander Ulges; Esther J Witsch; Gautam Pramanik; Matthias Klein; Katharina Birkner; Ulrike Bühler; Beatrice Wasser; Felix Luessi; Natascha Stergiou; Sarah Dietzen; Till-Julius Brühl; Toszka Bohn; Georg Bündgen; Horst Kunz; Ari Waisman; Hansjörg Schild; Edgar Schmitt; Frauke Zipp; Tobias Bopp
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-23       Impact factor: 11.205

6.  IL17RA gene variants and anti-TNF response among psoriasis patients.

Authors:  A Batalla; E Coto; J Gómez; N Eirís; D González-Fernández; C Gómez-De Castro; E Daudén; M Llamas-Velasco; R Prieto-Perez; F Abad-Santos; G Carretero; F S García; Y B Godoy; L F Cardo; B Alonso; S Iglesias; P Coto-Segura
Journal:  Pharmacogenomics J       Date:  2016-09-27       Impact factor: 3.550

Review 7.  New insights of T cells in the pathogenesis of psoriasis.

Authors:  Yihua Cai; Chris Fleming; Jun Yan
Journal:  Cell Mol Immunol       Date:  2012-06-18       Impact factor: 11.530

Review 8.  Biological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug-drug interaction implications.

Authors:  Jie Wang; Yow-Ming C Wang; Hae-Young Ahn
Journal:  AAPS J       Date:  2014-07-04       Impact factor: 4.009

9.  Higher levels of interleukin IL-17 and antigen-specific IL-17 responses in pulmonary sarcoidosis patients with Löfgren's syndrome.

Authors:  M Ostadkarampour; A Eklund; D Moller; P Glader; C Olgart Höglund; A Lindén; J Grunewald; J Wahlström
Journal:  Clin Exp Immunol       Date:  2014-11       Impact factor: 4.330

Review 10.  The influence of innate and adaptive immune responses on atherosclerosis.

Authors:  Joseph L Witztum; Andrew H Lichtman
Journal:  Annu Rev Pathol       Date:  2013-08-07       Impact factor: 23.472
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.